Vaccitech

PITCH

Founded in 2016 by Prof Adrian Hill and Prof Sarah Gilbert and created in the University of Oxford’s Jenner Institute, Vaccitech is focused on developing a universal flu vaccine, among a number of novel drug products. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications.